Quote:

---

if, in fact, Dr Makary's FDA reveals itself as more antithetical to Leronlimab than the previous FDA, I will accept the reality that LL will never be granted BTD or any form of approval during the pendency of Makary's administration. So far, however, based on Makary's bio at Johns Hopkins and his public statements that he wants to get breakthrough new drugs approved faster

---

It's much broader than just leronlimab. But with the limited data that leronlimab has available what do you think AI will make of it?